Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction

Aboseif, Sherif R.; Tamaddon, Kirk; Chalfin, Stuart; Freedman, Sheldon; Kaptein, John S.

doi:10.1016/s0090-4295(02)01630-8

Cited by 115 publications

(78 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…After gaining popularity in Europe, the United States Food and Drug Administration approved the use of sacral neuromodulation (InterStim 1 , Medtronic, Inc., Minneapolis, MN) in 1997 for the treatment of refractory urge incontinence. The same technology was approved in 1999 for the indication of urinary frequency and urgency and urinary retention [Aboseif et al, 2002].…”

Section: Introductionmentioning

confidence: 99%

Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women

Borawski

Foster

Webster

et al. 2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims: The purpose of this study was to determine whether a percutaneous needle electrode (PNE) technique or a surgical ¢rst stage lead placement (FSLP) better predicted whether a patient would progress to implantation of a pulse generator (IPG) in older urge incontinent women. Methods: Thirty subjects 55 years with refractory urge incontinence who had been selected to undergo a test stimulation procedure were randomized to either PNE or FSLP. Thirteen underwent PNE placement and seventeen underwent FSLP placement. If during the test stimulation period subjects had greater than 50% improvement in their incontinence parameters they quali¢ed for permanent lead and/or IPG implantation of the Interstim 1 device. Results: Twenty-one subjects (70%) responded to the test stimulation and underwent implantation, 15/17 (88%) in the FSLP group and 6/ 13 (46%) in the PNE group. Subjects who were randomized to the FSLP group were signi¢cantly more likely to proceed to implantation of the IPG (P ¼ 0.02) than those in the PNE group. There was no signi¢cant di¡erence in demographics, pre-test stimulation incontinence parameters or poststimulation visual analog pain scores between the randomized groups or between test stimulation responders and non-responders. When comparing FSLP and PNE responders, there was no signi¢-cant di¡erence in the percent improvement in 24-hr pad weight, daily pad usage, or daily incontinence. Conclusion: FSLP better predicted progression to implantation of the IPG than a test stimulation with a PNE in an older urge incontinent cohort. Neurourol. Urodynam. 26: 14^18, 2007. ß 2006

show abstract

Section: Introductionmentioning

confidence: 99%

Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women

Borawski

Foster

Webster

et al. 2006

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

“…Temporary PNE electrodes were removed in all patients who did not respond in the testing phase (based on NICE Guidelines) [5,20]. It was assumed that 7 % of patients who did not respond to SNS would have the device explanted [21][22][23][24][25][26], and that among those who did respond, 23 % would undergo surgical revision [21,[23][24][25][26][27]. It was assumed that individuals would have three physician visits for SNS device programming per year [28].…”

Section: Resource Use and Costmentioning

confidence: 99%

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

Freemantle¹,

Khalaf

Loveman

et al. 2015

Eur J Health Econ

View full text Add to dashboard Cite

The cost-effectiveness of onabotulinumtoxinA (BOTOX Ò ) 100 U ? best supportive care (BSC) was compared with BSC alone in the management of idiopathic overactive bladder in adult patients who are not adequately managed with anticholinergics. BSC included incontinence pads and, for a proportion of patients, anticholinergics and/or occasional clean intermittent catheterisation. A five-state Markov model was used to estimate total costs and outcomes over a 10-year period. The cohort was based on data from two placebo-controlled trials and a long-term extension study of onabotulinumtoxinA. After discontinuation of initial treatment, a proportion of patients progressed to downstream sacral nerve stimulation (SNS). Cost and resource use was estimated from a National Health Service perspective in England and Wales using relevant reference sources for 2012 or 2013. Results showed that onabotulinumtoxinA was associated with lower costs and greater health benefits than BSC in the base case, with probabilistic sensitivity analysis indicating an 89 % probability that the incremental cost-effectiveness ratio would fall below £20,000. OnabotulinumtoxinA remained dominant over BSC in all but two scenarios tested; it was also economically dominant when compared directly with SNS therapy. In conclusion, onabotulinumtoxinA appears to be a cost-effective treatment for overactive bladder compared with BSC alone.

show abstract

“…Aboseif et al . [71] reported that 18 of 20 patients had been able to stop CISC after a mean follow-up of 24 months. Swinn et al .…”

Section: Non-obstructive Urinary Retentionmentioning

confidence: 99%

“…Long-term success rates after 12-60 months of follow-up are summarized in Table 2 [40, [70][71][72][73]75] with a > 50% reduction in the number of catheterizations in 58-86%. The cure rate, being the percentage of patients not needing to perform CISC at all, was 50-55% after 41-48 months of follow-up.…”

Section: Non-obstructive Urinary Retentionmentioning

confidence: 99%

An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?

Bosch

2010

BJU International

View full text Add to dashboard Cite

Sacral neuromodulation as an effective treatment for refractory pelvic floor dysfunction

Cited by 115 publications

References 22 publications

Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women

Predicting implantation with a neuromodulator using two different test stimulation techniques: A prospective randomized study in urge incontinent women

OnabotulinumtoxinA in the treatment of overactive bladder: a cost-effectiveness analysis versus best supportive care in England and Wales

An update on sacral neuromodulation: where do we stand with this in the management of lower urinary tract dysfunction in 2010?

Contact Info

Product

Resources

About